Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Opus Genetics, Inc.NASDAQ: IRD
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 40.0% from a year ago
Common stock stood at $7K at the end of Q1 FY2026, up 40.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +51.8% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +40.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 7K USD
- Year-over-year change
- +133.3%
- 4-year CAGR
- +36.8%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7K | +133.3% |
| FY2024 | 2024-12-31 | 3K | +50.0% |
| FY2023 | 2023-12-31 | 2K | +0.0% |
| FY2022 | 2022-12-31 | 2K | +0.0% |
| FY2021 | 2021-12-31 | 2K | — |
Common Stock vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's Mar 2026 common stock of $7K is the 7th highest of the 10 companies compared; the peer median is $11K.
- Its year-over-year change of +40.0% is the 5th highest of 9, against a peer median of +33.5%.
- Common stock amounts to 0.0% of total assets for IRD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $385K | +44.7% | -51.3% | 0.2% | |
| Mar 2026 | $90K | +45.2% | +45.9% | 0.2% | |
| Mar 2026 | $69.77K | +90.3% | +48.5% | 0.1% | |
| Mar 2026 | $63.58K | +45.6% | +135.7% | 0.2% | |
| Mar 2026 | $11K | +22.2% | +11.2% | 0.0% | |
| Mar 2026 | $10K | +11.1% | -56.9% | 0.0% | |
IRDOpus Genetics, Inc. | Mar 2026 | $7K | +40.0% | +51.8% | 0.0% |
| Mar 2026 | $7K | +16.7% | +14.5% | 0.0% | |
| Mar 2026 | $1K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IRD) | $11K | +33.5% | +12.8% | 0.0% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.